Go Pro
OTCMKTS:SNYNF

Sanofi (SNYNF) Stock Price, News & Analysis

Sanofi logo
$90.22 -0.88 (-0.96%)
As of 10:42 AM Eastern

About Sanofi Stock (OTCMKTS:SNYNF)

Advanced

Key Stats

Today's Range
$90.06
$90.22
50-Day Range
$81.29
$93.45
52-Week Range
$80.74
$106.34
Volume
571 shs
Average Volume
31,035 shs
Market Capitalization
N/A
P/E Ratio
29.25
Dividend Yield
3.10%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sanofi is a multinational biopharmaceutical company headquartered in Paris, France, specializing in the research, development and manufacturing of prescription medicines, vaccines and consumer healthcare products. With a strategic focus on specialty care, vaccines, and general medicines, Sanofi’s portfolio addresses a broad range of therapeutic areas, including diabetes, cardiovascular disease, oncology, immunology and rare diseases. The company operates through distinct business segments, each dedicated to advancing patient care through innovative therapies and preventive solutions.

In its pharmaceuticals segment, Sanofi develops and markets biologics and small molecules designed to treat chronic and acute conditions. The company’s specialty care division focuses on treatment for rare diseases, multiple sclerosis and oncology, while its general medicines unit provides treatments for established therapeutic areas such as cardiovascular health and internal medicine. Sanofi Pasteur, the vaccines arm, is one of the world’s largest producers of immunizations, offering a wide range of vaccines against influenza, meningitis, polio and other infectious diseases. Sanofi Consumer Healthcare extends the company’s reach into over-the-counter remedies, vitamins and nutritional supplements, enhancing overall wellness and self-care.

Sanofi traces its modern structure to the 2004 merger of Sanofi-Synthélabo and Aventis, which brought together complementary portfolios in pharmaceuticals and vaccines. In 2011, the company simplified its branding to “Sanofi,” uniting its global operations under a single identity. Over the years, Sanofi has expanded through strategic acquisitions and collaborations, strengthening its pipeline in emerging fields such as gene therapy, mRNA vaccines and digital health. The company maintains an active research presence with multiple R&D centers in Europe, North America and Asia, collaborating with academic institutions and industry partners to accelerate innovation.

Today, Sanofi employs more than 100,000 people worldwide and serves patients in over 100 countries. The company has significant commercial operations across Europe, North America, Latin America, Asia and Africa, leveraging local expertise to address regional health challenges. Since September 2019, Sanofi has been led by Chief Executive Officer Paul Hudson, under whose stewardship the company has emphasized agility in research, patient-centricity and sustainable growth. Sanofi continues to pursue a long-term vision of improving global health through scientific excellence, expansive access programs and a commitment to corporate responsibility.

AI Generated. May Contain Errors.

Receive SNYNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNYNF Stock News Headlines

Sanofi (SNYNF) Gets a Hold from UBS
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Deutsche Bank Keeps Their Buy Rating on Sanofi (SNYNF)
Jefferies Reaffirms Their Buy Rating on Sanofi (SNYNF)
See More Headlines

SNYNF Stock Analysis - Frequently Asked Questions

Sanofi's stock was trading at $97.2950 at the beginning of the year. Since then, SNYNF stock has decreased by 7.3% and is now trading at $90.2240.

Shares of SNYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/31/2026
Next Earnings (Estimated)
10/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:SNYNF
CIK
1121404
Fax
N/A
Employees
91,600
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
29.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:SNYNF) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners